ProfileGDS4814 / ILMN_1752199
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 88% 88% 85% 88% 88% 85% 87% 89% 92% 88% 88% 91% 87% 88% 88% 87% 89% 87% 89% 89% 88% 87% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)319.66288
GSM780708Untreated after 4 days (C2_1)303.6388
GSM780709Untreated after 4 days (C3_1)233.71585
GSM780719Untreated after 4 days (C1_2)331.41788
GSM780720Untreated after 4 days (C2_2)309.32188
GSM780721Untreated after 4 days (C3_2)223.89985
GSM780710Trastuzumab treated after 4 days (T1_1)294.99287
GSM780711Trastuzumab treated after 4 days (T2_1)373.49789
GSM780712Trastuzumab treated after 4 days (T3_1)503.6492
GSM780722Trastuzumab treated after 4 days (T1_2)321.94588
GSM780723Trastuzumab treated after 4 days (T2_2)307.8288
GSM780724Trastuzumab treated after 4 days (T3_2)487.1191
GSM780713Pertuzumab treated after 4 days (P1_1)278.20787
GSM780714Pertuzumab treated after 4 days (P2_1)308.26888
GSM780715Pertuzumab treated after 4 days (P3_1)313.5688
GSM780725Pertuzumab treated after 4 days (P1_2)280.35487
GSM780726Pertuzumab treated after 4 days (P2_2)375.9589
GSM780727Pertuzumab treated after 4 days (P3_2)294.34487
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)366.08389
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)344.79289
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)339.73888
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)292.93487
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)326.31688